journal article·2017-10-25Open access

Aspartic acid derivatized hydroxylated fullerenes as drug delivery vehicles for docetaxel: an explorative study

Nagarani Thotakura, Gajanand Sharma, Bhupinder Singh, Vipin Kumar, Kaisar Raza

Abstract

The objective of the present study was to deliver docetaxel to cancerous cells with enhanced efficacy and safety profile, using aspartic acid linked fullerenols. This aspartic acid derivatized fullerenol conjugate linked with docetaxel was characterized by UV, FT-IR and NMR spectroscopy. Studies for particle size, PDI, zeta potential and FE-SEM were also performed. The conjugate was evaluated for release kinetics, cancer cell cytotoxicity, cellular uptake using confocal laser microscopy and also for pharmacokinetic profile. Cytotoxic studies proved that there was almost 4.3 folds decrease in IC50 with significantly enhanced cellular uptake of the nanometric conjugates. It was observed that the bioavailability was enhanced by 5.8 folds when compared to that of pure DTX. The developed nanoconstructs were erythrocyte compatible and offered decreased protein binding. The findings are encouraging and offer a novel carrier with enhanced efficacy and safety of a drug, belonging to BCS class IV.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Fullerene Chemistry and Applications · Graphene and Nanomaterials Applications · Polymer Nanocomposite Synthesis and Irradiation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Rajasthan, India;

Division of Pharmaceutics, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India;

UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites, Panjab University, Chandigarh, India

Funding

Science and Engineering Research Board, Department of Science and Technology

References (46)

Show source-provided references
1. 10.1631/jzus.B120009810.1631/jzus.B1200098 ↗
2. Prakash O · Am J Pharmacol Sci · 2013 · 1 · 104
3. 10.1021/ar00028a00510.1021/ar00028a005 ↗
4. 10.1016/j.ijpharm.2015.09.01610.1016/j.ijpharm.2015.09.016 ↗
5. 10.2174/138161282266616052414492610.2174/1381612822666160524144926 ↗
6. 10.3390/ijms1503351910.3390/ijms15033519 ↗
7. 10.1016/j.biomaterials.2012.09.03910.1016/j.biomaterials.2012.09.039 ↗
8. 10.1166/asl.2012.425110.1166/asl.2012.4251 ↗
9. 10.1016/j.ijpharm.2006.06.02310.1016/j.ijpharm.2006.06.023 ↗
10. 10.1186/s11671-015-1206-710.1186/s11671-015-1206-7 ↗
11. 10.2174/221173850566617030114223210.2174/2211738505666170301142232 ↗
12. 10.1016/0008-6223(92)90062-210.1016/0008-6223(92)90062-2 ↗
13. 10.1039/c3994000030510.1039/c39940000305 ↗
14. 10.1002/3527603492.ch410.1002/3527603492.ch4 ↗
15. 10.1039/b002908o10.1039/b002908o ↗
16. 10.1007/s11051-005-7523-510.1007/s11051-005-7523-5 ↗
17. 10.1039/B601582B10.1039/B601582B ↗
18. 10.1007/978-1-62703-475-3_510.1007/978-1-62703-475-3_5 ↗
19. 10.2131/jts.34.55510.2131/jts.34.555 ↗
20. 10.1016/j.taap.2010.08.00810.1016/j.taap.2010.08.008 ↗
21. 10.1016/j.msec.2017.03.07310.1016/j.msec.2017.03.073 ↗
22. 10.1016/j.ijbiomac.2016.03.06410.1016/j.ijbiomac.2016.03.064 ↗
23. 10.1002/cjoc.2004022092610.1002/cjoc.20040220926 ↗
24. 10.1016/0026-265X(65)90063-910.1016/0026-265X(65)90063-9 ↗
25. 10.1016/j.ijbiomac.2016.08.08010.1016/j.ijbiomac.2016.08.080 ↗
26. 10.1021/acs.molpharmaceut.6b0018310.1021/acs.molpharmaceut.6b00183 ↗
27. 10.1208/s12249-016-0681-110.1208/s12249-016-0681-1 ↗
28. 10.1016/j.ijpharm.2017.01.02110.1016/j.ijpharm.2017.01.021 ↗
29. 10.1016/j.msec.2017.03.05710.1016/j.msec.2017.03.057 ↗
30. 10.1021/acschemneuro.7b0004110.1021/acschemneuro.7b00041 ↗
31. 10.1007/s10856-012-4651-110.1007/s10856-012-4651-1 ↗
32. 10.1021/acschemneuro.6b0042810.1021/acschemneuro.6b00428 ↗
33. Daniel WW · 2013
34. Dash S · Acta Pol Pharm. · 67 · 217
35. 10.1186/1556-276X-8-42010.1186/1556-276X-8-420 ↗
36. Pavia DL · 2009
37. 10.1039/c002570d10.1039/c002570d ↗
38. 10.1021/cm070114a10.1021/cm070114a ↗
39. 10.1016/j.clay.2006.11.00910.1016/j.clay.2006.11.009 ↗
40. 10.1016/B978-0-08-100557-6.00001-810.1016/B978-0-08-100557-6.00001-8 ↗
41. 10.1177/10600280890230070610.1177/106002808902300706 ↗
42. 10.1016/j.jhazmat.2017.04.04110.1016/j.jhazmat.2017.04.041 ↗
43. 10.1039/c2sm06811g10.1039/c2sm06811g ↗
44. 10.1016/j.addr.2007.06.00810.1016/j.addr.2007.06.008 ↗
45. 10.1111/j.1742-7843.2008.00266.x10.1111/j.1742-7843.2008.00266.x ↗
46. Shargel L · 2004